Dear Ms. Muir:


We acknowledge receipt of your submissions dated March 8 and 11, April 21 and 27 (2), June 1 and 9, July 6, August 10, 11 and 29 (2), September 20, October 6, 11, 19 (2), 24 and 27, November 1 and 14, December 13, 14, 20, 21, 22 (2) and 28, 2000; and January 11, February 28, April 20 and 30, June 21, July 19, August 2 and September 13, 27, and 28 (2), 2001. Your submission of August 2, 2001 constituted a complete response to our April 27, 2001 action letter.

This new drug application provides for the use of NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) for the prevention of pregnancy in women who elect to use this product as a method of contraception.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, text for the patient package insert) and the immediate container and carton labeling submitted September 28, 2001. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar
material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-187." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your postmarketing study commitments in your submission dated September 27, 2001. These commitments are listed below.

1. Initiate study 34232 as per the protocol previously submitted.

   Protocol Submission: Submitted the protocol on April 20, 2001
   Study Start: Within six months of the date of this letter
   Final Report Submission: Within six months of study completion

2. Submit a plan for follow-up of all spontaneous reports of pregnancy with NuvaRing® use to obtain information regarding duration of fetal exposure to NuvaRing® for each pregnancy and pregnancy outcomes, including live births, stillbirths, premature births, spontaneous abortions, and congenital anomalies. The plan, including 6 month intervals for submitting data and a 5 year time span for follow-up post approval.

   Protocol Submission: Within six months of the date of this letter
   Study Start: First day of marketing the product
   Final Report Submission: Within six months following the five year reporting period

We also remind you of your agreement to provide a non-automated alternative for the in vitro release analytical method that would allow validation of the methodology.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "Postmarketing Study Protocol", "Postmarketing Study Final Report", or "Postmarketing Study Correspondence."

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We are waiving the pediatric study requirement for this action on this application.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Reproductive and Urologic Drug Products and two copies of both the promotional materials and the package insert directly to:
Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Jennifer Mercier, B.S., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Florence Houn, M.D., M.P.H., F.A.C.P.
Director
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure